Regenerative Medicine Regulations: A Clinician's Guide

Regenerative medicine is the fastest-growing area of clinical practice and one of the most regulated. The gap between what practitioners are doing and what they understand about the regulatory framework is exactly where the risk lives. This guide is the educational foundation — the same material covered in the Genademy Regulations course.

Why regulatory literacy matters

A 2022 scoping review in Regenerative Medicine found clinicians lack adequate basic science and regulatory knowledge to navigate the field. The consequence is real: practitioners adopting therapies without understanding their regulatory status expose patients, practices, and their own licenses to avoidable risk. Understanding the framework is not bureaucracy — it is the professional floor.

The FDA framework: 351 vs 361

Most regenerative therapies fall into one of two regulatory lanes:

• Section 351 products (PHS Act) — regulated as drugs, biologics, or devices. These require premarket approval or an investigational pathway (IND, IDE) before lawful clinical use.
• Section 361 HCT/Ps (21 CFR 1271) — human cells, tissues, and cellular/tissue-based products that are minimally manipulated, intended for homologous use, and not combined with other articles. These can be regulated solely under 361 without premarket approval.

Whether a specific product is 351 or 361 depends on its characteristics, not its marketing. Clinicians should verify the status of every product they use.

State scope of practice

Scope is set by state law and professional boards — and it varies widely. A physician practicing under a medical license may have different authority than an NP, PA, or nurse in the same state. Key questions every practitioner must answer for their own situation:

• Does my license authorize the procedures I plan to offer?
• Do I need collaborative or supervisory arrangements?
• What does my state medical board say about regenerative therapies specifically?
• What are my prescribing and delegation limits?

Documentation standards

Documentation is where compliance is proven. The professional minimum includes:

• Informed consent — specific to the therapy, its regulatory status, and its risks
• Source and lot traceability — batch records for every product used
• Storage and handling records — chain of custody for temperature-sensitive biologics
• Adverse event reporting — recognized pathways and timelines
• Treatment records — indications, technique, outcomes, and follow-up

Marketing and claims discipline

The most common regulatory failure in this space is not the procedure — it is the marketing. Making therapeutic claims for products that are investigational or not FDA-approved for the discussed use is the fastest path to enforcement attention. The rule is simple: educate, don't advertise; characterize, don't claim.

Where to learn this properly

This guide is the overview. The Genademy Regulations course takes the full Eight-Step path — Science, Evidence, Regulation, Clinical Reasoning, Technique, Safety, Implementation, Outcomes — with the depth practicing clinicians need, taught by practitioners who practice what they teach.

This guide is for educational purposes and does not constitute legal or regulatory advice. Regulatory status varies by product, state, and over time. Practitioners are responsible for verifying their own scope of practice, the current regulatory status of any product, and applicable law before clinical use. Genademy provides professional education for licensed healthcare practitioners.